Table 3 shows the results of uni- and multivariate analyses of factors potentially related to PFS in HCC patients under Lenvatinib treatment. For multivariate analysis, variables that had already been identified as risk factors for PFS after Lenvatinib treatment in univariate analysis were selected, and the following two covariates of HCC were taken into account: age and sex. In multivariate analysis, the combination of FGF19-i and Ang-2-d (Hazzard Ratio, 0.171; 95% CI, 0.037–0.793; p = 0.0240) was independently associated with poor PFS. The gene discussed is ANGPT2; the disease is hepatocellular carcinoma.